Skip to main content

Advertisement

SpringerLink
Log in

Follow-up of local (stage I and stage II) non-small-cell lung cancer after surgical resection

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Non-small-cell lung cancer (NSCLC) is responsible for more deaths each year in the United States than is any other malignancy. Early stage disease can be cured with surgical resection. Postoperative surveillance for recurrent disease and the development of second malignancies are important parts of the overall treatment plan. Follow-up strategies have been analyzed and guidelines (most notably those of the National Comprehensive Cancer Network [NCCN]) have been published. However, common practice often does not comply with these rationally developed guidelines. Understanding the general principles of effective surveillance may improve compliance with the guidelines and may lead to more cost-effective management. New methods of surveillance, postoperative risk stratification, and emerging therapies may alter these recommendations for postoperative surveillance of patients with early stage NSCLC in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics, 2000. CA Cancer J Clin 2000, 50:7–33.

    Article  PubMed  CAS  Google Scholar 

  2. Ettinger,DS,Cox JD,Ginsberg RJ, et al.: Non-small-cell lung cancer practice guidelines. The National Comprehensive Cancer Network. Oncology (Huntingt) 1996, 10(Suppl 11):81–111. Evidence based guidelines for the management of most cancers, including follow-up strategies.

    CAS  Google Scholar 

  3. Baldini EH, DeCamp MM, Katz MS, et al.: Patterns of recurrence and outcome for patients with clinical stage II non-small-cell lung cancer. Am J Clin Oncol 1999, 22:8–14.

    Article  PubMed  CAS  Google Scholar 

  4. Nesbitt JC, Putnam JB, Walsh GL, et al.: Survival in early stage non-small-cell lung cancer. Ann Thorac Surg 1995, 60:466–472.

    Article  PubMed  CAS  Google Scholar 

  5. Walsh GL, Winn RJ: Baseline institutional compliance with NCCN guidelines: non-small-cell lung cancer. Oncology 1997, 11:161–170.

    PubMed  CAS  Google Scholar 

  6. Naunheim KS, Virgo KS, Coplin MA, Johnson FE: Clinical surveillance testing after lung cancer operation. Ann Thorac Surg 1995, 60:1612–1616.

    Article  PubMed  CAS  Google Scholar 

  7. Hiebert CA: The“cured” lung cancer patient: is followup by the surgeon worthwhile? Ann Thorac Surg 1995, 60:1557–1558.

    Article  PubMed  CAS  Google Scholar 

  8. Shields TW: Postoperative lung cancer surveillance. Who, what, when, and why? Chest 1997, 111:11–12.

    PubMed  CAS  Google Scholar 

  9. Edelman MJ, Meyers FJ, Siegel D: The utility of followup testing after curative cancer therapy: a critical review and economic analysis. J Gen Intern Med 1997, 12:318–331. Comprehensive review of the principles of follow-up testing and an evaluation of strategies employed in several malignancies.

    Article  PubMed  CAS  Google Scholar 

  10. Harpole DH Jr, Herndon JE 2nd, Young WG JR, Sabiston DC Jr: Stage I non-small-cell lung cancer: a multivariate analysis of treatment methods and patterns of recurrence. Cancer 1995, 76:787–796.

    Article  PubMed  Google Scholar 

  11. Thomas P, Rubinstein L: Cancer recurrence after resection: T1N0 non-small-cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1990, 49:242–246.

    Article  PubMed  CAS  Google Scholar 

  12. Ludwig Lung Cancer Study Group: Patterns of failure in patients with resected stage I and II non-small-cell carcinoma of the lung. Ann Surg 1987, 205:67–71.

    Article  Google Scholar 

  13. Curran WJ, Herbert SH, Stafford PM, et al.: Should patients with post-resection locoregional recurrence of lung cancer receive aggressive therapy? Int J Radiat Oncol Biol Phys 1992, 24:25–30.

    PubMed  Google Scholar 

  14. Gabler A, Liebig S: Reoperation for bronchial carcinoma. Thorax 1980, 35:668–670.

    Article  PubMed  CAS  Google Scholar 

  15. Westeel V, Choma D, Clement F, et al.: Relevance of an intensive postoperative follow-up after surgery for non-small-cell lung cancer. Ann Thorac Surg 2000, 70:1185–1190.

    Article  PubMed  CAS  Google Scholar 

  16. Marino P, Pampallona S, Preatoni A, et al.: Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest 1994, 106:861–865.

    PubMed  CAS  Google Scholar 

  17. Johnson BE: Second lung cancers in patients after treatment for an initial lung cancer. J Natl Cancer Inst 1998, 90:1335–1345. This paper reviews the literature of recurrent cancer after definitive treatment of small-cell cancer in a comprehensive fashion.

    Article  PubMed  CAS  Google Scholar 

  18. Younes RN, Gross JL, Deheinzelin D: Follow-up in lung cancer: how often and for what purpose? Chest 1999, 115:1494–1499.

    Article  PubMed  CAS  Google Scholar 

  19. Virgo KS, McKirgan LW, Caputo MCA, et al.: Posttreatment management options for patients with lung cancer. Ann Surg. 1995, 222:700–710.

    Article  PubMed  CAS  Google Scholar 

  20. Walsh GL, O’Connor M, Willis KM, et al.: Is follow-up of lung cancer patients after resection medically indicated and cost-effective? Ann Thorac Surg. 1995, 60:1563–1572.

    Article  PubMed  CAS  Google Scholar 

  21. Marcus PM, Bergstralh EJ, Fagerstrom RM, et al.: Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst 2000, 92:1308–1316.

    Article  PubMed  CAS  Google Scholar 

  22. Downey RJ: Follow-up of patients with completely resected lung cancer. Chest 1999, 115:1487–1489.

    Article  PubMed  CAS  Google Scholar 

  23. Marcus PM: Lung cancer screening: an update. J Clin Oncol 2001, 19(suppl 18):83–86S.

    Google Scholar 

  24. Diederich S, Wormanns D, Lenzen H, et al.: Screening for asymptomatic early bronchogenic carcinoma with low dose CT of the chest. Cancer 2000, 89(suppl 11):2483–2484.

    Article  PubMed  CAS  Google Scholar 

  25. Sone S, Li F, Yang ZG, et al.: Results of three-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner. Br J Cancer 2001, 84:25–32.

    Article  PubMed  CAS  Google Scholar 

  26. Henschke CI: Early lung cancer action project: annual screening using single-slice helical CT. Prin Pract Oncol 2001, 15:1–12.

    Google Scholar 

  27. Bury T, Corhay JL, Duysinx B, et al.: Value of FDG-PET in detecting residual or recurrent non-small-cell lung cancer. Eur Respir J 1999, 14:1376–1380.

    Article  PubMed  CAS  Google Scholar 

  28. Inoue T, Kim EE, Komaki R, et al.: Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med 1995, 36:788–793.

    PubMed  CAS  Google Scholar 

  29. Patz EF, Lowe VJ, Hoffman JM, et al.: Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose. Radiology 1994, 191:379–382.

    PubMed  Google Scholar 

  30. Berman CG, Clark RA: Positron emission tomography in initial staging and diagnosis of persistent or recurrent disease. Curr Opin Oncol 2000, 12:132–137.

    Article  PubMed  CAS  Google Scholar 

  31. Berlin NI, Buncher CR, Fontana RS, et al.: The National Cancer Institute Cooperative Early Lung Cancer Detection Program. Results of the initial screen (prevalence). Early lung cancer detection. Introduction. Am Rev Resp Dis 1984, 130:545–549.

    PubMed  CAS  Google Scholar 

  32. Strovel JW, Stamberg J, Highsmith WE, et al.: Plasma telomerase activity predicts response and relapse in lung cancer. Proc Am Soc Clin Oncol 2000, 19:486a.

    Google Scholar 

  33. Pujol JL, Boher JM, Grenier J, Quantin X: CYFRA 21-1, neuron specific enolase and prognosis of non-smallcell lung cancer: prospective study in 621 patients. Lung Cancer 2001, 31:221–231.

    Article  PubMed  CAS  Google Scholar 

  34. Karnak D, Ulubay G, Kayacan O, et al.: Evaluation of CYFRA 21-1: a potential tumor marker for non-smallcell lung carcinomas. Lung 2001, 179:57–65.

    Article  PubMed  CAS  Google Scholar 

  35. Stieber P, Aimmermann A, Reinmiedl J, et al.: CYFRA 21-1 in the early diagnosis of recurrent disease in non-small-cell lung carcinomas. Anticancer Res 1999, 19:2665–2668.

    PubMed  CAS  Google Scholar 

  36. Paone G, DeAngelis G, Greco S, et al.: Evaluation of response to chemotherapy in patients affected with non-small-cell lung cancer by means of three tumour markers elaborated by discriminant analysis. Respir Med 1997, 91:361–367.

    Article  PubMed  CAS  Google Scholar 

  37. Edelman MJ, Khanwani SL: Advanced non-small-cell lung cancer. Curr Treat Options Oncol 2001, 2:51–62.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, University of Maryland Greenebaum Cancer Center, 22 South Greene Street, 21201, Baltimore, MD, USA

    Martin J. Edelman MD & Julie Schuetz CRNP

Authors
  1. Martin J. Edelman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julie Schuetz CRNP
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Edelman, M.J., Schuetz, J. Follow-up of local (stage I and stage II) non-small-cell lung cancer after surgical resection. Curr. Treat. Options in Oncol. 3, 67–73 (2002). https://doi.org/10.1007/s11864-002-0043-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-002-0043-y

Keywords

Search

Navigation